Supplementary Data1 from IK-175, an Oral Aryl Hydrocarbon Receptor Inhibitor, Alone and with Nivolumab in Patients with Advanced Solid Tumors and Urothelial Carcinoma

David Henry Aggen; Meredith Ann McKean; Hoffman-Censits Jean; Nehal J. Lakhani; Omar Alhalabi; Elizabeth Ann Guancial; Babar Bashir; Isaac Alex Bowman; Alan Tan; Trupti Lingaraj; Nerymar Ortiz-Otero; Wilmin P. Bartolini; Marissa Timothy; Katherine J. Kim; Katherine A. Kacena; Sergio Santillana; Jason J. Luke

doi:10.1158/1078-0432.31006912

Supplementary Data1 from IK-175, an Oral Aryl Hydrocarbon Receptor Inhibitor, Alone and with Nivolumab in Patients with Advanced Solid Tumors and Urothelial Carcinoma

2026 Open access

Read full text

Authors: David Henry Aggen, Meredith Ann McKean, Hoffman-Censits Jean, Nehal J. Lakhani, Omar Alhalabi, Elizabeth Ann Guancial, Babar Bashir, Isaac Alex Bowman, Alan Tan, Trupti Lingaraj, Nerymar Ortiz-Otero, Wilmin P. Bartolini

+5 more

Marissa Timothy, Katherine J. Kim, Katherine A. Kacena, Sergio Santillana, Jason J. Luke

DOI: 10.1158/1078-0432.31006912

Cited by: 0

Fields of Study & Subjects

Bladder and Urothelial Cancer Treatments Peptidase Inhibition and Analysis Drug Transport and Resistance Mechanisms

Publication details

Publication date: 6 January 2026